Revolution Medicines
RVMD
134 hedge funds and large institutions have $2.07B invested in Revolution Medicines in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 41 reducing their positions, and 23 closing their positions.
415% more call options, than puts
Call options by funds: $3.85M | Put options by funds: $748K
24% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 41
19% more capital invested
Capital invested by funds: $1.74B → $2.07B (+$332M)
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
2.69% less ownership
Funds ownership: 100.76% → 98.07% (-2.7%)
6% less funds holding
Funds holding: 142 → 134 (-8)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$56.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.7M |
| 3 |
AG
Artal Group
Luxembourg
|
+$21.3M |
| 4 |
JP Morgan Chase
New York
|
+$17.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$42.5M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$42.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$17.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$11.3M |
| 5 |
Millennium Management
New York
|
-$8.35M |
RVMD Hedge Fund Activity: Q4 2022 in Review
134 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2022, worth a combined $2.07B — up 19% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RVMD and 18 opened new positions — a net loss of 5 holders — while 41 trimmed existing stakes and 51 added.
The largest buyer was EcoR1 Capital, adding an estimated $56.5M. The largest seller was Deerfield Management, cutting an estimated $42.5M.
- 134 institutional investors held Revolution Medicines (RVMD) as of Q4 2022, down from 142 in Q3 2022.
- Funds reported $2.07B of Revolution Medicines stock for Q4 2022, up 19% quarter-over-quarter.
- 18 funds opened new Revolution Medicines positions in Q4 2022 and 23 closed out, a net change of -5 holders.
- The largest Revolution Medicines buyer in Q4 2022 was EcoR1 Capital, an estimated $56.5M added.
- The largest Revolution Medicines seller in Q4 2022 was Deerfield Management, an estimated $42.5M sold.
Based on aggregated 13F filings for Q4 2022.